Brought to you by 
Dynavax gets $50mm in special funding from Symphony
24 Jun 2020
Executive Summary
Private equity firm Symphony Capital has formed financing and clinical development vehicle Symphony Dynamo and funded the new company with $50mm to continue development on Dynavax's cancer, hepatitis B and hepatitis C programs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Special-Purpose Financing Vehicle
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dynavax gets $50mm in special funding from Symphony
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice